object
infect
increas
significantli
recent
year
close
associ
cervic
cancer
hiv
infect
lack
success
vaccin
develop
emerg
drug
resist
commonli
use
drug
emphas
urgent
need
altern
antivir
infect
arbidol
arb
demonstr
broad
spectrum
antivir
drug
exhibit
immunomodulatori
properti
affect
life
cycl
studi
investig
efficaci
mechan
arb
vivo
vitro
explor
clinic
applic
arb
method
efficaci
arb
infect
vitro
examin
cpe
mtt
assay
vagin
model
establish
monitor
chang
histopatholog
inflammatori
cytokin
express
h
e
stain
elisa
respect
efficaci
arb
evalu
accordingli
furthermor
flow
cytometri
use
determin
ratio
cell
peripher
blood
vagin
anim
consid
balanc
efficaci
pharmacokinet
arb
ointment
strictli
prepar
observ
formul
efficaci
differ
compar
oral
dose
form
result
show
vitro
tc
ic
arb
si
respect
indic
arb
present
effect
activ
dosedepend
manner
result
timecours
assay
suggest
arb
affect
late
stage
replic
howev
arb
inhibit
viral
attach
cell
penetr
vivo
result
show
arb
ointment
improv
surviv
rate
prolong
surviv
time
reduc
reproduct
tract
injuri
mice
infect
regul
cytokin
express
balanc
lymphocyt
ratio
peripher
blood
particip
regul
immun
respons
conclus
arb
show
activ
vitro
dosedepend
manner
play
role
inhibit
late
replic
cycl
viru
vagin
model
success
establish
accord
immunomodul
outcom
respond
better
arb
ointment
form
oral
form
sexual
transmit
diseas
std
million
acquir
everi
day
worldwid
common
group
notifi
infecti
diseas
countri
particularli
age
group
year
infant
eight
pathogen
link
std
greatest
incid
among
four
current
incur
viral
infect
hepat
b
herp
simplex
viru
hsv
human
immunodefici
viru
hiv
human
papillomaviru
hpv
herpesviru
famili
mediums
envelop
dna
viru
divid
subfamili
hsv
belong
human
herpesvirida
subfamili
hsv
one
common
pathogen
human
frequent
report
respons
herpet
enceph
herp
kerat
genit
herp
neonat
infect
myocard
diseas
wide
spread
human
human
two
distinct
type
hsv
infect
central
nervou
system
produc
cold
sore
produc
genit
herp
estim
million
peopl
age
approxim
popul
global
age
rang
carrier
viru
risk
mortal
left
untreat
infect
usual
caus
characterist
lesion
mucou
membran
skin
surround
genit
initi
primari
infect
infect
peopl
experi
sporad
episod
viral
reactiv
outbreak
addit
seropreval
women
higher
men
transmiss
childbirth
caus
complic
neonat
result
brain
damag
death
simultan
infect
increas
risk
hiv
acquisit
approxim
threefold
increas
risk
even
greater
newlyacquir
infect
nucleosid
analog
acyclovir
acv
discov
current
food
drug
administr
fda
approv
treatment
infect
clinic
trial
modul
cours
diseas
decreas
transmiss
risk
cure
diseas
furthermor
acv
singl
mechan
action
requir
activ
site
coordin
easili
lead
drug
resist
crossresist
resist
major
threat
could
reduc
impact
antivir
drug
sti
worldwid
especi
among
hivinfect
patient
region
immunocompromis
patient
limit
treatment
option
avail
therefor
urgent
need
develop
novel
drug
differ
mechan
action
infect
due
diseas
sever
arb
small
molecul
indol
deriv
develop
russian
center
medicin
chemistri
alreadi
licens
russia
china
report
antiinfluenza
agent
immunomodulatori
properti
clinic
applic
limit
region
interfer
virusinduc
membran
fusion
also
degrad
viral
rna
mrna
inhibit
protein
synthesi
therebi
block
earli
replic
viru
addit
arb
also
induc
interferon
ifn
releas
host
peripher
blood
recent
studi
extend
inhibitori
activ
human
virus
includ
respiratori
syncyti
viru
rsv
rhinoviru
rhv
hepat
c
viru
hcv
coxsackieviru
cvb
sever
acut
respiratori
syndrom
sar
herp
simplex
viru
type
influenza
mutant
strain
resist
amantadin
oseltamivir
ys
boriskin
et
al
demonstr
arb
prophylact
effect
hcv
infect
inhibit
hcv
replic
arb
exert
even
significantli
antivir
activ
hantaan
viru
htnv
reduc
patholog
chang
decreas
viral
load
regul
serum
level
infect
tissu
arb
inhibit
viru
replic
vitro
vivo
mechan
block
viral
adsorpt
late
stage
viral
replic
thu
exert
longlast
antivir
effect
addit
recent
data
show
arb
exert
direct
antivir
effect
earli
viral
replic
sar
viru
cell
specif
mechan
clinic
applic
still
need
studi
perfetto
et
al
reveal
arb
exhibit
abil
influenc
replic
reduct
viral
express
modul
cytokin
pathway
arb
show
strong
therapeut
effect
even
better
acv
infect
rabbit
model
viral
kerat
two
trial
superior
efficaci
arb
compar
ribavirin
demonstr
patient
influenza
viru
prophylact
use
arb
reduc
acut
respiratori
viru
infect
incid
secondari
viralbacteri
pneumonia
base
arb
chemic
structur
metabolit
may
play
antivir
antiinflammatori
role
could
use
drug
prototyp
could
identifi
human
urin
administr
singl
mgdose
arb
healthi
peopl
hand
clinic
valu
arb
underestim
due
region
applic
china
russia
arb
uniqu
pharmacolog
action
low
toxic
good
toler
consid
promis
broadspectrum
antivir
drug
previou
work
result
clarifi
activ
arb
suppress
influenza
viru
propag
modul
express
inflammatori
cytokin
vitro
vivo
explor
pharmacolog
activ
differ
arb
administr
method
human
infecti
diseas
better
understand
antivir
mechan
action
improv
clinic
promot
first
evalu
vitro
efficaci
arb
nontox
concentr
determin
potenti
antivir
mechan
access
effect
arb
patholog
morpholog
inflammatori
cytokin
level
chang
peripher
blood
lymphocyt
subset
mous
vagin
model
therefor
studi
provid
support
arb
could
use
clinic
provid
protect
std
herp
take
prophylact
treat
patient
decreas
risk
hiv
acquisit
african
green
monkey
kidney
cell
line
vero
cell
purchas
american
tissu
cultur
collect
atcc
cultur
use
dulbecco
modifi
eagl
medium
dmem
gibco
supplement
fetal
bovin
serum
fb
glutamin
humidifi
atmospher
co
cell
grown
monolay
complet
medium
chang
everi
day
trypsin
seed
varieti
micropl
serumfre
medium
experi
viru
strain
gift
institut
tropic
medicin
guangzhou
univers
chines
medicin
passag
titr
vero
cell
laboratori
store
use
arb
lot
suppli
shijiazhuang
pharmaceut
co
ltd
hebei
china
acyclovir
acv
lot
lraa
purchas
sigma
compani
usa
arb
powder
acv
dissolv
mgml
dimethyl
sulfoxid
dmso
filter
membran
store
necessari
dmem
use
dilut
substanc
suitabl
concentr
ointment
prepar
previous
describ
modif
mg
arb
powder
extract
three
time
ml
ethanol
ethanol
extract
combin
concentr
simultan
mg
vaselin
follow
mg
oliv
oil
melt
anoth
beaker
oili
phase
mixtur
extract
heat
approxim
hot
solut
slowli
ad
oili
phase
continu
stir
mixtur
cool
form
arb
ointment
averag
bodi
weight
mice
calcul
g
accord
experiment
rule
approxim
mg
arb
extract
name
mg
arb
ointment
administ
vagin
daili
dosag
arb
ointment
assum
mgkgd
vero
cell
seed
plate
cell
per
well
cell
grown
confluent
monolay
cultur
aspir
wash
pb
twice
drug
ad
dilut
cell
incub
co
day
mtt
solut
mgml
ad
cell
incub
co
addit
h
supernat
discard
dimethylsulfoxid
dmso
ad
well
absorb
measur
nm
use
micropl
reader
toxic
concentr
tc
calcul
use
reedmuench
method
antivir
activ
arb
detect
cytopathogen
effici
cpe
method
mtt
assay
drug
dissolv
dmem
medium
serial
dilut
seven
concentr
vero
cell
inocul
plate
grown
confluenc
approxim
h
wash
twice
pb
treatment
assay
dilut
tcid
ad
well
incub
co
h
supernat
discard
drug
ad
well
incub
co
anoth
h
inhibitori
concentr
ic
calcul
reedmuench
method
pretreat
assay
perform
cell
treat
arb
indic
concentr
h
infect
direct
action
assay
viru
preincub
arb
indic
concentr
h
ad
cell
cultur
infect
incub
co
h
medium
aspir
cell
rins
pb
incub
medium
anoth
h
final
supernat
collect
tcid
assay
attach
assay
describ
de
logu
et
al
perform
studi
minor
modif
cell
monolay
infect
viru
presenc
serial
dilut
arb
indic
concentr
incub
h
medium
aspir
remov
free
viru
infect
cell
wash
pb
three
time
ad
medium
h
incub
supernat
collect
tcid
assay
accord
publish
paper
penetr
assay
vero
cell
perform
minor
modif
cell
monolay
infect
viru
incub
h
allow
attach
arb
ad
indic
concentr
cultur
incub
h
allow
entri
viru
infect
cell
monolay
treat
pb
ph
min
inactiv
nonpenetr
viru
subsequ
pb
remov
fresh
medium
ad
infect
cell
h
incub
supernat
collect
determin
viru
titer
tcid
assay
determin
possibl
stage
viral
life
cycl
target
arb
timecours
assay
perform
previous
describ
minor
modif
vero
cell
seed
plate
densiti
cellsml
cell
cultur
co
cell
grew
monolay
wash
twice
pb
vero
cell
monolay
infect
tcid
treat
arb
indic
time
point
incub
co
h
viru
supernat
cell
harvest
viru
yield
determin
tcid
method
evalu
activ
arb
vivo
studi
establish
mous
vagin
model
vagin
infect
anim
experi
perform
anim
research
center
guangzhou
institut
respiratori
health
femal
spf
kunm
mice
g
randomli
divid
group
mice
group
follow
normal
group
viru
group
acvtreat
mgkgd
group
arbtreat
mgkgd
group
arb
ointmenttr
mgkgd
group
ointment
vehicl
group
progesteron
ml
inject
subcutan
day
prior
infect
make
anim
enter
estrou
cycl
increas
suscept
mice
arb
treatment
group
treat
arb
mgkgd
oral
intravagin
twice
per
day
day
arb
ointment
appli
micropipett
spread
infect
site
acv
mgkgd
given
oral
accord
manufactur
instruct
mice
normal
neg
group
administ
equival
amount
salin
ointment
vehicl
group
treat
equival
amount
control
ointment
infect
solut
pfuml
use
infect
vagin
surfac
area
salin
administ
normal
control
mice
group
observ
daili
day
calcul
surviv
rate
death
protect
surviv
time
bodi
weight
chang
infect
assay
experi
vagin
lavag
obtain
day
infect
evalu
viral
shed
report
literatur
input
viru
could
detect
within
h
inocul
viral
shed
infect
anim
reach
maximum
day
precool
dmem
deliv
vagina
pipet
time
maxim
viral
recoveri
vagina
rins
twice
collect
vagin
lavag
mix
remov
drug
might
remain
lavag
fluid
mix
lavag
fluid
ultrafilt
amicon
ultra
ultrafiltr
tube
liquid
centrifug
tube
recov
total
volum
adjust
dmem
ml
tube
supernat
place
vero
cell
determin
viral
titer
tcid
accord
reedmuench
method
cytopath
effect
cpe
score
h
later
mice
whose
lavag
cultur
display
cpe
consid
infect
assay
rapid
sensit
observ
visibl
lesion
death
depend
hormon
immun
statu
mice
determin
whether
arb
could
affect
immun
statu
mice
spleen
score
spleen
index
arb
treatment
mous
bodi
weight
record
mice
sacrif
dissect
spleen
rins
salin
dri
absorb
paper
spleen
weigh
spleen
index
spleen
index
inhibit
rate
calcul
accord
follow
formula
group
four
mice
set
histopatholog
experi
anim
group
sacrif
day
post
viral
exposur
dissect
vagina
vagina
harvest
fix
paraformaldehyd
solut
subsequ
tissu
process
paraffin
embed
cut
section
standard
hematoxylin
eosin
h
e
stain
finish
treatment
day
infect
blood
immedi
collect
three
randomli
select
mice
group
serum
obtain
centrifug
rmin
min
use
detect
serum
cytokin
level
proinflammatori
cytokin
evalu
use
enzymelink
immunosorb
assay
elisa
usa
r
system
use
accord
manufactur
instruct
od
nm
read
immedi
use
microtit
plate
reader
serum
aliquot
ep
tube
store
sampl
repeatedli
frozen
thaw
anim
model
establish
describ
section
day
infect
peripher
blood
taken
mous
eyebal
retroorbit
punctur
blood
incub
fitclabel
antimous
monoclon
antibodi
ebiosci
pelabel
antimous
monoclon
antibodi
ebiosci
antimous
monoclon
antibodi
ebiosci
min
dark
wash
time
pb
stain
blood
incub
red
blood
cell
lysi
buffer
min
blood
analyz
percentag
cell
flow
cytometri
experiment
result
analyz
use
flowjo
softwar
data
process
use
graphpad
prism
express
mean
sd
statist
differ
group
determin
use
student
ttest
multipl
group
oneway
anova
analysi
use
compar
mean
p
consid
signific
differ
group
grow
monolay
vero
cell
treat
arb
concentr
investig
arb
cytotox
incub
h
cell
viabil
evalu
cpe
mtt
assay
arb
show
toxic
toxic
concentr
tc
arb
vero
cell
fig
calcul
regress
analysi
dosevi
curv
similarli
tc
arb
cell
pretreat
assay
viru
pretreat
assay
drug
incub
h
fig
therefor
adopt
experiment
maximum
concentr
cell
surviv
rate
antivir
efficaci
arb
vitro
first
evalu
mtt
assay
continu
arb
presenc
h
post
infect
dosedepend
inhibit
infect
observ
inhibitori
concentr
ic
valu
fig
si
addit
effect
posit
control
drug
acv
investig
comparison
viru
control
group
show
good
protect
effect
ic
valu
si
tabl
drug
exert
antivir
activ
modifi
membran
compon
target
cell
directli
target
viru
elucid
whether
possibl
mechan
activ
arb
cell
virus
pretreat
arb
incub
viru
yield
assay
result
indic
pretreat
vero
cell
arb
concentr
ml
significantli
inhibit
replic
ic
si
data
shown
addit
pretreat
arb
profoundli
depress
progeni
viral
yield
valu
predict
accord
best
fit
nonlinear
regress
formula
calcul
set
data
si
abbrevi
select
index
si
mean
low
toxic
si
mean
high
toxic
low
effect
si
mean
effect
ic
si
data
shown
result
suggest
antivir
activ
arb
exist
cell
virus
viral
entri
character
specif
stage
replic
cycl
imped
arb
perform
timeofaddit
assay
character
inhibitori
action
vitro
briefli
arb
remov
vero
cell
indic
time
viru
addit
h
pi
h
pi
h
pi
subsequ
progeni
viru
yield
determin
tcid
method
shown
fig
arb
inhibit
progeni
viru
product
approxim
p
treatment
last
h
signific
reduct
progeni
viru
observ
arb
remov
h
pi
h
pi
p
result
reveal
arb
probabl
inhibit
viral
assembl
releas
late
step
replic
cycl
unlik
acv
inhibit
virusencod
thymidin
kinas
dna
polymeras
activ
middl
step
life
cycl
accord
result
timeofaddit
assay
arb
affect
late
stage
infect
verifi
whether
arb
block
replic
earli
stage
attach
entri
assay
individu
carri
arb
shown
fig
viru
yield
attach
penetr
assay
significantli
decreas
arb
concentr
result
consist
hypothesi
viral
inhibit
occur
late
stage
replic
cycl
evalu
activ
arb
vivo
test
drug
mous
model
vagin
mice
observ
daili
symptom
onset
bodi
weight
surviv
time
number
death
record
day
surviv
rate
mice
administ
arb
ointment
intravagin
mgkgd
therapi
initi
day
viral
inocul
unexpectedli
acvtreat
group
fig
tabl
arb
ointment
mgkgd
also
inhibit
decreas
bodi
weight
fig
suppress
increas
mous
spleen
index
compar
ointment
vehicl
group
fig
interestingli
averag
surviv
time
averag
bodi
weight
chang
spleen
index
show
signific
differ
compar
viru
group
p
arb
mgkgd
oral
administ
progeni
viru
replic
vagina
assess
femal
mice
infect
follow
intravagin
infect
vagin
lavag
fluid
collect
wash
repeatedli
precool
dmem
dpi
quantifi
viru
titer
tcid
assay
fig
consist
acvtreat
group
arb
ointment
mgkgd
could
significantli
attenu
progeni
viru
replic
infect
vagina
statist
signific
compar
ointment
vehicl
group
p
wherea
present
similarli
high
titer
arb
oral
treatment
group
viru
group
p
fig
day
post
infect
mani
neutrophil
necrot
area
lymphocyt
aggreg
microscop
observ
vagin
submucosa
adipos
tissu
mice
viru
group
ointment
vehicl
group
fig
e
expect
unappar
vagin
mucos
lesion
observ
arb
ointmenttr
group
fig
neutrophil
infiltr
hemorrhag
mucos
layer
significantli
differ
acvtreat
group
fig
also
notic
vagin
tissu
femal
mice
treat
oral
mgkgd
arb
lesion
seriou
sever
acut
purul
inflamm
necrosi
vagin
epithelium
seen
untreat
infect
tissu
fig
result
clearli
demonstr
potent
activ
arb
ointment
mgkgd
vagin
caus
infect
vagin
tissu
evalu
whether
arb
affect
virusinduc
inflammatori
cytokin
elisa
assay
conduct
attach
assay
cell
monolay
infect
tcid
absenc
presenc
arb
indic
concentr
incub
h
penetr
assay
cell
monolay
infect
viru
incub
h
arb
ad
indic
concentr
anoth
h
incub
infect
cell
monolay
treat
pb
ph
min
fresh
medium
ad
remov
acid
pb
time
fresh
medium
ad
h
incub
supernat
collect
determin
viru
titer
tcid
assay
point
repres
mean
sd
three
independ
experi
day
postinfect
shown
fig
significantli
downregul
follow
infect
posttreat
arb
ointment
mgkgd
compar
level
mice
viru
group
ointment
vehicl
group
p
howev
level
show
signific
differ
p
assess
influenc
arb
ointment
cell
subgroup
peripher
blood
measur
cell
popul
peripher
blood
mice
treat
drug
left
untreat
flow
cytometri
signific
higher
ratio
cell
found
peripher
blood
arb
ointmenttr
group
acvtreat
group
viru
group
tabl
hsv
one
pathogen
caus
common
sexual
transmit
infect
sti
infect
alway
lead
sever
diseas
genit
herp
vagin
enceph
increas
risk
hiv
acquisit
infect
recogn
import
marker
infect
hsv
persist
indefinit
shed
year
reactiv
probabl
one
reason
preval
genit
herp
develop
countri
increas
recent
decad
therefor
develop
novel
antivir
strategi
critic
requir
counteract
emerg
previou
studi
shown
arb
inhibitori
effect
envelop
nonenvelop
rna
dna
virus
includ
variant
strain
amantadin
oseltamivir
target
differ
stage
viru
replic
cycl
recent
report
activ
arb
suppress
influenza
viru
propag
vitro
furthermor
paper
found
nontox
concentr
arb
effect
block
cytopath
effect
induc
dosedepend
manner
late
stage
viru
replic
cycl
direct
inactiv
effect
interfer
adher
viru
cell
surfac
consist
data
document
viru
hcv
viru
hantaan
viru
base
result
specul
arb
like
affect
assembl
releas
progeni
viru
howev
studi
necessari
explain
specif
mechan
impact
replic
cycl
weight
chang
surviv
rate
life
protect
rate
import
indic
evalu
efficaci
antivir
drug
studi
howev
oral
administr
arb
slightli
improv
weight
loss
surviv
rate
releas
viru
particl
infect
vagin
site
caus
infect
show
signific
differ
compar
viru
group
may
distribut
drug
mice
rapid
extens
intragastr
administr
arb
maximum
concentr
drug
mainli
appear
digest
tract
stomach
small
intestin
larg
intestin
follow
target
organ
lung
spleen
liver
concentr
genitalia
low
due
drug
pharmacokinet
also
like
arb
rather
metabolit
exert
antivir
antiinflammatori
effect
base
specif
prepar
arb
ointment
treatment
vagin
infect
site
interestingli
result
show
arb
ointment
could
significantli
allevi
vagin
patholog
increas
surviv
rate
prolong
surviv
time
delay
weight
loss
induc
viral
infect
well
inhibit
releas
progeni
viru
activ
immun
respons
effici
way
interfer
viral
infect
system
respons
viru
elimin
cytokin
play
import
role
activ
immun
system
regul
immun
respons
promot
viral
clearanc
suppress
cytokin
potenti
control
sever
virusinduc
inflammatori
complic
essenti
reduc
mortal
recent
studi
found
patient
infect
hsv
especi
recurr
immunolog
defect
associ
lack
cell
perfetto
b
et
al
note
arb
could
regul
hsvinduc
overexpress
cytokin
previous
report
sever
proinflammatori
cytokin
induc
influenza
rant
downregul
posttreat
arb
mice
ferret
therefor
hypothes
arb
may
suppress
infect
modul
express
inflammatori
cytokin
could
act
immunomodul
drive
host
cell
exert
antivir
respons
document
spleen
largest
peripher
immun
organ
whose
structur
directli
affect
host
immun
function
certain
extent
spleen
index
one
import
indic
immun
function
valu
chang
reflect
state
bodi
immun
function
hypersensit
occur
paper
result
show
spleen
index
valu
dpi
mice
significantli
increas
compar
mice
normal
control
group
p
indic
immun
function
mice
compromis
howev
contrari
previou
report
may
due
differ
infect
time
calcul
spleen
index
day
infect
howev
document
indic
earli
stage
viral
infect
immun
function
disord
due
infect
result
compensatori
hyperplasia
spleen
spleen
index
valu
viru
group
ointment
vehicl
group
higher
normal
group
prolong
infect
time
condit
infect
mice
gradual
increas
spleen
atrophi
anoth
reason
might
explain
differ
differ
rout
infect
directli
inocul
vagina
activ
immun
system
earlier
oral
administr
base
result
arb
ointment
delay
compensatori
hyperplasia
spleen
weight
loss
caus
indic
arb
ointment
effect
modul
bodi
immun
function
balanc
bodi
cytokin
level
suppress
disord
caus
infect
elimin
viral
antigen
mainli
reli
cellular
immun
humor
immun
especi
clearanc
intracellular
virus
among
immun
particip
cell
cell
play
import
role
studi
shown
absenc
antibodi
initi
replicationdefici
virusinduc
cell
respons
may
effect
infect
cell
essenti
secret
cytokin
promot
cell
enter
tissu
jia
zhu
et
al
found
genit
tract
subclin
infect
recur
virusspecif
cell
accumul
around
sensori
nerv
genit
tract
indic
cell
play
import
role
clear
activ
viru
time
relat
cytokin
secret
cell
may
involv
cellular
immun
respons
viral
infect
result
show
ratio
cell
peripher
blood
ointment
vehicl
group
viru
group
lower
normal
group
interestingli
ratio
significantli
higher
treatment
suggest
arb
ointment
exert
immunomodulatori
effect
enhanc
immun
function
elimin
host
prevent
recurr
genit
herp
taken
togeth
result
suggest
arb
potent
possess
antivir
immunomodulatori
activ
simultan
block
prolifer
mous
vagin
model
moreov
success
prepar
arb
ointment
could
significantli
reduc
express
viral
induc
cytokin
result
tissu
damag
consist
immunohistochemistri
analysi
show
arb
ointment
dramat
attenu
recruit
inflammatori
factor
vagin
epithelium
despit
precis
fig
express
level
peripher
blood
mice
infect
arb
treatment
femal
mice
infect
intravagin
viru
serum
collect
peripher
blood
experiment
group
day
post
infect
supernat
determin
elisa
assay
compar
viru
group
p
p
effect
arb
cell
subgroup
blood
mice
x
n
note
compar
viru
group
p
molecular
mechan
arb
regul
host
immun
remain
unclear
ointment
prepar
use
studi
yet
stabl
clinic
applic
therefor
studi
requir
focu
develop
topic
formul
hope
effect
stabil
arb
promis
drug
addit
degre
find
extend
hsvrelat
diseas
kerat
vagin
requir
investig
